Cargando…

SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19

The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis, as these people are believed to be at increased risk of infection, especially those being treated with disease-modifying therapies. Therefore, the objective of this review was to describe how COVID-19 affects p...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Jurado, Ana, Escribano, Begoña M., Agüera, Eduardo, Caballero-Villarraso, Javier, Galván, Alberto, Túnez, Isaac
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253265/
https://www.ncbi.nlm.nih.gov/pubmed/35788744
http://dx.doi.org/10.1007/s00415-022-11237-1
_version_ 1784740443728117760
author Muñoz-Jurado, Ana
Escribano, Begoña M.
Agüera, Eduardo
Caballero-Villarraso, Javier
Galván, Alberto
Túnez, Isaac
author_facet Muñoz-Jurado, Ana
Escribano, Begoña M.
Agüera, Eduardo
Caballero-Villarraso, Javier
Galván, Alberto
Túnez, Isaac
author_sort Muñoz-Jurado, Ana
collection PubMed
description The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis, as these people are believed to be at increased risk of infection, especially those being treated with disease-modifying therapies. Therefore, the objective of this review was to describe how COVID-19 affects people who suffer from Multiple Sclerosis, evaluating the risk they have of suffering an infection by this virus, according to the therapy to which they are subjected as well as the immune response of these patients both to infection and vaccines and the neurological consequences that the virus can have in the long term. The results regarding the increased risk of infection due to treatment are contradictory. B-cell depletion therapies may cause patients to have a lower probability of generating a detectable neutralizing antibody titer. However, more studies are needed to help understand how this virus works, paying special attention to long COVID and the neurological symptoms that it causes.
format Online
Article
Text
id pubmed-9253265
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-92532652022-07-05 SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19 Muñoz-Jurado, Ana Escribano, Begoña M. Agüera, Eduardo Caballero-Villarraso, Javier Galván, Alberto Túnez, Isaac J Neurol Review The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis, as these people are believed to be at increased risk of infection, especially those being treated with disease-modifying therapies. Therefore, the objective of this review was to describe how COVID-19 affects people who suffer from Multiple Sclerosis, evaluating the risk they have of suffering an infection by this virus, according to the therapy to which they are subjected as well as the immune response of these patients both to infection and vaccines and the neurological consequences that the virus can have in the long term. The results regarding the increased risk of infection due to treatment are contradictory. B-cell depletion therapies may cause patients to have a lower probability of generating a detectable neutralizing antibody titer. However, more studies are needed to help understand how this virus works, paying special attention to long COVID and the neurological symptoms that it causes. Springer Berlin Heidelberg 2022-07-05 2022 /pmc/articles/PMC9253265/ /pubmed/35788744 http://dx.doi.org/10.1007/s00415-022-11237-1 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Muñoz-Jurado, Ana
Escribano, Begoña M.
Agüera, Eduardo
Caballero-Villarraso, Javier
Galván, Alberto
Túnez, Isaac
SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19
title SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19
title_full SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19
title_fullStr SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19
title_full_unstemmed SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19
title_short SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19
title_sort sars-cov-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253265/
https://www.ncbi.nlm.nih.gov/pubmed/35788744
http://dx.doi.org/10.1007/s00415-022-11237-1
work_keys_str_mv AT munozjuradoana sarscov2infectioninmultiplesclerosispatientsinteractionwithtreatmentsadjuvanttherapiesandvaccinesagainstcovid19
AT escribanobegonam sarscov2infectioninmultiplesclerosispatientsinteractionwithtreatmentsadjuvanttherapiesandvaccinesagainstcovid19
AT agueraeduardo sarscov2infectioninmultiplesclerosispatientsinteractionwithtreatmentsadjuvanttherapiesandvaccinesagainstcovid19
AT caballerovillarrasojavier sarscov2infectioninmultiplesclerosispatientsinteractionwithtreatmentsadjuvanttherapiesandvaccinesagainstcovid19
AT galvanalberto sarscov2infectioninmultiplesclerosispatientsinteractionwithtreatmentsadjuvanttherapiesandvaccinesagainstcovid19
AT tunezisaac sarscov2infectioninmultiplesclerosispatientsinteractionwithtreatmentsadjuvanttherapiesandvaccinesagainstcovid19